Navigation Links
Palatin Announces Strategic Realignment of Operations
Date:9/24/2010

anotide for female sexual dysfunction (FSD): We are submitting protocols and a meeting request to the FDA for initiation of a Phase 2 clinical trial of subcutaneously administered bremelanotide for women with FSD, and anticipate that the meeting will be held late in the fourth quarter of calendar 2010 or early in the first quarter of calendar 2011. Assuming concurrence of the FDA, and depending on financial resources, this Phase 2 clinical trial for women with FSD could start as early as the first half of calendar 2011.

New peptides for sexual dysfunction: We intend to advance one or more of the peptides we have developed to preclinical toxicology and other studies required by the FDA prior to initiating human clinical trials.

Asthma

PL-3994 for acute severe asthma: We have planned a proof-of-concept human trial for asthma using a subcutaneously administered formulation of PL-3994, and will submit an Investigational New Drug application to the FDA in the fourth quarter of calendar 2010 for this trial. We also have an inhalation formulation of PL-3994 under development. Depending on financial resources, either or both the proof-of-concept human trial and preclinical inhalation toxicity studies could start as early as the first quarter of calendar 2011.

Obesity

Active work by Palatin under the collaboration portion of its research collaboration and license agreement with AstraZeneca concluded in January 2010, but we are still providing certain clinical trial related and other services to AstraZeneca. We are eligible for milestone payments totaling up to $145 million, with up to $85 million contingent upon development and regulatory milestones and the balance on achievement of sales targets, plus royalties on sales of approved products. AstraZeneca has responsibility for product commercialization, product discovery and development costs.

Realignment and Workforce Reductions'/>"/>

SOURCE Palatin Technologies, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Palatin Technologies, Inc. to Raise $2.0 Million Dollars in Registered Direct Offering
2. Palatin Technologies, Inc. Reports Second Quarter Fiscal Year 2010 Results; Teleconference and Webcast to be held on February 16, 2010
3. Palatin Technologies, Inc. Issued U.S. Patent for Heart Failure Drug Candidate
4. Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2010 Results; Teleconference and Webcast to be held on November 16, 2009
5. Palatin Technologies, Inc. Reports Fourth Quarter and Fiscal Year End 2009 Results; Teleconference and Webcast to be held on September 8, 2009
6. Palatin Technologies, Inc. to Report Fourth Quarter and Fiscal Year 2009 Results; Teleconference and Webcast to be held on September 8, 2009
7. Palatin Technologies to Present at the Rodman & Renshaw 11th Annual Global Investment Conference
8. Palatin Technologies, Inc. to Raise $3.1 Million in Registered Direct Offering
9. Palatin Technologies, Inc. Reports Positive Bremelanotide Study; Improved Safety Profile with Subcutaneous Administration
10. Palatin Technologies, Inc. Receives U.S. Patent Allowance for Heart Failure Drug Candidate
11. Palatin Technologies Listing Compliance Plan Accepted by NYSE Alternext US
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/26/2015)... -- BioEnterprise today announced that Northeast Ohio ... billion in growth funding during the past 13 years.  ... state – including the Ohio Third Frontier - and ... been raised in the past five years. ... BioEnterprise Midwest Healthcare Growth Capital  Report.   ...
(Date:2/26/2015)... Innovation is more urgent than ... parts of the world and transforming global markets ... manufacturing to health care, disruption is constantly underway. ... socio-political trends shake the foundations of established business ... CEOs to survive the next wave of mega-change. ...
(Date:2/26/2015)... 2015  Dyadic International, Inc. ("Dyadic") (OTCQX: DYAI), ... technologies are used to develop, manufacture and sell ... chemical, biopharmaceutical and industrial enzyme industries, announced today ... year ending December 31, 2014 after market close ... a conference call that day at 5:00 p.m. ...
(Date:2/26/2015)... Feb. 26, 2015 Tauriga Sciences, Inc. (OTCQB: TAUG) ... with interests in the natural wellness sector and in ... that its products will be featured at the SEC ... 27 th Annual Growth Stock Conference on March ... 1 Ritz Carlton Drive, Dana Point ...
Breaking Biology Technology:More Than $2 Billion Invested in Northeast Ohio Bioscience Start-Up Companies Since 2002 2More Than $2 Billion Invested in Northeast Ohio Bioscience Start-Up Companies Since 2002 3More Than $2 Billion Invested in Northeast Ohio Bioscience Start-Up Companies Since 2002 4One Million Acts of Innovation Canada Creates Partnership with The Economist Events’ Innovation Forum 2Dyadic International To Announce Fourth Quarter 2014 Financial Results And Host Conference Call On Wednesday, March 11, 2015 2Dyadic International To Announce Fourth Quarter 2014 Financial Results And Host Conference Call On Wednesday, March 11, 2015 3SEC Compliance Featuring Products From Tauriga Sciences, Inc. at ROTH Capital Conference 2SEC Compliance Featuring Products From Tauriga Sciences, Inc. at ROTH Capital Conference 3SEC Compliance Featuring Products From Tauriga Sciences, Inc. at ROTH Capital Conference 4
... (Nasdaq: OPTR ) today announced its financial results for ... loss for the first quarter of 2009 of $10.9 million, or ... This compares to a net loss for the first quarter ... and development expenses in the first quarter of 2009 were $8.8 ...
... NOTTINGHAM, UK, May 7 Human Genome Sciences, ... Biopharma, a part of Novozymes (Nasdaq: NZYM B), ... license agreement to allow both companies to expand ... http://www.newscom.com/cgi-bin/prnh/20080416/HGSLOGO )Under the amended ...
... Molecular,Therapeutics (Euronext: AMT), a leader in the field ... the first patient in a preregistration,clinical trial with ... (LPLD), a seriously debilitating and,potentially lethal disease. , ... has been designed to gather additional,data on the ...
Cached Biology Technology:Optimer Pharmaceuticals Reports First Quarter 2009 Financial Results 2Optimer Pharmaceuticals Reports First Quarter 2009 Financial Results 3Optimer Pharmaceuticals Reports First Quarter 2009 Financial Results 4Optimer Pharmaceuticals Reports First Quarter 2009 Financial Results 5Human Genome Sciences and Novozymes Announce Amendment to Albumin Fusion License Agreement 2Human Genome Sciences and Novozymes Announce Amendment to Albumin Fusion License Agreement 3Human Genome Sciences and Novozymes Announce Amendment to Albumin Fusion License Agreement 4AMT Starts Preregistration Trial for Glybera(TM) 2AMT Starts Preregistration Trial for Glybera(TM) 3
(Date:1/22/2015)... 13, 2015 Technology Showcase, Hall E -   EyeLock ... today announced it will showcase its EyeLock ID technology integrated ... Department of Energy,s Oak Ridge National Laboratory (ORNL) ... EyeLock,s iris identity authentication technology is being used to validate ...
(Date:1/22/2015)... NXT-ID, Inc. (NASDAQ: NXTD and NXTDW) a biometric ... recent success of the Wocket™ smart wallet at CES 2015 in ... named as one of the "11 Hot Products at CES" in a ... CES So Far" by Newseveryday.com and "The top 10 gadgets from CES ...
(Date:1/22/2015)... 22, 2015 , Europe,s ... The European Patent Office to present a video retrospective of ... to be featured: Christofer Toumazou and Sophie Wilson ... and winners of the Award   Starting on 22 ...
Breaking Biology News(10 mins):EyeLock Debuts First Iris Authentication Technology Embedded in 3D Printed Automobile 2EyeLock Debuts First Iris Authentication Technology Embedded in 3D Printed Automobile 3CES Response for NXT-ID's Wocket Smart Wallet Kicks Off 2015 2CES Response for NXT-ID's Wocket Smart Wallet Kicks Off 2015 3Ten Years of the European Inventor Award: A Retrospective Look at the Inventors and Ideas That Have Changed Our Lives 2Ten Years of the European Inventor Award: A Retrospective Look at the Inventors and Ideas That Have Changed Our Lives 3
... rhinovirus (HRV), the leading cause of most common colds, ... respiratory failure, graft dysfunction and death. The two were ... suffered clinically significant respiratory infection from HRV in both ... that HRV affects only upper airway tissue. , The ...
... chemical dopamine has been thought of as the brain's "pleasure ... rewards a person or animal for one activity or another. ... and heroin amplify this effect ?an action that may lie ... new study from the University of Michigan adds a new ...
... Alberta in Edmonton, Canada have been able to put a ... defies classification. , The findings, published recently in the Journal ... the creature, named Horolodectes sunae, for the unusual shape of ... years ago, soon after the dinosaurs went extinct, in a ...
Cached Biology News:Common cold virus leads to death in lung transplant patients 2Pleasure and pain: Study shows brain's 'pleasure chemical' is involved in response to pain too 2Pleasure and pain: Study shows brain's 'pleasure chemical' is involved in response to pain too 3Pleasure and pain: Study shows brain's 'pleasure chemical' is involved in response to pain too 4Researchers give name to ancient mystery creature 2
This CLS number is a new product number, created to easily match Cornings product number. If showing no availability yet, please order under the old Sigma-Aldrich number (F1676) or contact customer s...
Mouse monoclonal [YPF19] to Yersinia pestis F1 antigen ( Abpromise for all tested applications)....
... This CLS number is a ... match Cornings product number. If showing ... the old Sigma-Aldrich number (E6152) or ... Comp Dim: H diam. 11.25 ...
... gradient system uses three Adept CE 4100 ... a flow rate in one microlitre increaments. ... scanning detector, provides added flexibility. The ... a photodiode array detection and provides superior ...
Biology Products: